The Universal Character of the Tumor-Associated Antigen Survivin
- 15 October 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (20), 5991-5994
- https://doi.org/10.1158/1078-0432.ccr-07-0686
Abstract
Survivin is expressed in most human neoplasms, but is absent in normal, differentiated tissues. Survivin is a bifunctional inhibitor of apoptosis protein that has been implicated in protection from apoptosis and regulation of mitosis. Several clinical trials targeting survivin with a collection of different approaches from small molecule antagonists to immunotherapy are currently under way. With regard to the latter, spontaneous anti-survivin T-cell reactivity has been described in cancer patients suffering from a huge range of cancers of different origin, e.g., breast and colon cancer, lymphoma, leukemia, and melanoma. Thus, survivin may serve as a universal target antigen for anticancer immunotherapy. Accordingly, down-regulation of survivin as a means of immune escape would severely inflict the survival capacity of tumor cells, which highlights this protein as a prime target candidate for therapeutic vaccinations against cancer. Data from several ongoing phase I/II trials targeting survivin for patients with advanced cancer will provide further information about this idea.Keywords
This publication has 33 references indexed in Scilit:
- Persistence of survivin specific T cells for seven years in a melanoma patient During domplete remissionCancer Biology & Therapy, 2006
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytesLeukemia, 2004
- Adenovirus-Mediated Transfer of siRNA against Survivin Induced Apoptosis and Attenuated Tumor Cell Growth in Vitro and in VivoMolecular Therapy, 2004
- Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonistsSeminars in Oncology, 2003
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastomaOncogene, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSINGAnnual Review of Immunology, 1998